How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

799 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease (PubMed)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease 28761423 2018 11 13 1673-5374 12 6 2017 Jun Neural regeneration research Neural Regen Res Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease. 916-917 10.4103/1673-5374.208572 Castillo Willian O WO 0000-0001-9138-1248 Department of Biology, University of Cauca, Popayan, Colombia. Aristizabal-Pachon Andres Felipe AF Department of Genetics

Full Text available with Trip Pro

2017 Neural Regeneration Research

22. The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study (PubMed)

The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study 28130004 2018 10 02 2018 11 13 1573-2509 188 2017 10 Schizophrenia research Schizophr. Res. The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study. 141-143 S0920-9964(17)30041-5 10.1016/j.schres.2017.01.028 Cohen Alex S AS Louisiana State University, Department of Psychology, USA. Electronic address: acohen@lsu.edu (...) Netherlands Schizophr Res 8804207 0920-9964 0 Antipsychotic Agents 0D3Q044KCA Galantamine 50-56-6 Oxytocin IM Adult Antipsychotic Agents therapeutic use Facial Expression Galantamine therapeutic use Humans Interpersonal Relations Interview, Psychological Middle Aged Neuropsychological Tests Oxytocin therapeutic use Psychotic Disorders drug therapy psychology Schizophrenia drug therapy Schizophrenic Psychology Social Behavior Speech Production Measurement Treatment Outcome Video Recording Voice drug

Full Text available with Trip Pro

2017 Schizophrenia Research

23. Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study (PubMed)

Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study The aim of this work was to enhance the transportation of the galantamine to the brain via ascorbic acid grafted PLGA-b-PEG nanoparticles (NPs) using SVCT2 transporters of choroid plexus. PLGA-b-PEG copolymer was synthesized and characterized by 1H NMR, gel permeation chromatography, and differential scanning calorimetry. PLGA-b-PEG-NH2 and PLGA-b-mPEG NPs were prepared

Full Text available with Trip Pro

2017 Scientific reports

24. Rehabilitative success after brain trauma by augmenting a sub-therapeutic dose of environmental enrichment with galantamine (PubMed)

Rehabilitative success after brain trauma by augmenting a sub-therapeutic dose of environmental enrichment with galantamine Environmental enrichment (EE) confers benefits after traumatic brain injury (TBI) when provided daily for > 6 hours, but not 2 or 4 hours, which more accurately reflects the daily amount of clinical rehabilitation. The lack of benefit with sub-therapeutic EE suggests that augmentation with galantamine (GAL), which enhances cognition after TBI, may be indicated to confer

Full Text available with Trip Pro

2017 Neurorehabilitation and neural repair

25. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]

[Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary (...) commission: rivastigmine patches and galantamine] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cologne: Institut fuer

2012 Health Technology Assessment (HTA) Database.

26. In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease (PubMed)

In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease Alzheimer's disease (AD) is a chronic pathological condition that leads to neurodegeneration, loss of intellectual abilities, including cognition and memory, and ultimately to death. It is widely recognized that AD is a multifactorial disease, where different pathological cascades (mainly amyloid and tau) contribute to neural death and to the clinical outcome related

Full Text available with Trip Pro

2016 Scientific reports

27. Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil (PubMed)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil This study compares the efficacy of the cholinesterase inhibitor (ChEI) galantamine on cognition in patients with mild-to-moderate Alzheimer's dementia (AD) who were either naïve to ChEI drugs or who had failed a trial of the ChEI donepezil.Outpatients with AD were sequentially referred for screening and enrollment. Current outpatients who had taken donepezil for at least 6 months (...) without demonstrated efficacy on cognition were switched to galantamine (switched group). New outpatients with no ChEI prescription history were classified as the naïve group and were given galantamine. The primary outcome measures for the between-group comparison were response rate on cognition at 26 and 52 weeks (categorical) and change on the Korean version of the Alzheimer's Disease Assessment Scale-cognitive subscale (dimensional). Secondary cognitive outcomes were measured using the subset

Full Text available with Trip Pro

2016 Psychiatry investigation

28. Subarachnoid Hemorrhage Recovery And Galantamine

Subarachnoid Hemorrhage Recovery And Galantamine Subarachnoid Hemorrhage Recovery And Galantamine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Subarachnoid Hemorrhage Recovery And Galantamine (SAHRANG (...) Information provided by (Responsible Party): HuiMahn Alex Choi, The University of Texas Health Science Center, Houston Study Details Study Description Go to Brief Summary: The purpose of this study is to examine the effects of the study drug--Galantamine—on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH. Condition or disease Intervention/treatment Phase Subarachnoid

2016 Clinical Trials

29. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. (PubMed)

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. A large, prospective, 2-year, randomized study in patients with mild-to-moderate Alzheimer's disease or mixed dementia demonstrated reductions in mortality and cognitive/functional decline in galantamine-treated patients. A post-hoc analysis was conducted to study the effect of (the presence or absence (...)  < 0.0001) and DAD scores (58.0 (23.49) vs 62.5 (20.52), p < 0.0001) than nonusers. Mortality rates (per 100 patient-years) in memantine nonusers (n = 1549) were lower for galantamine (1.39) vs placebo-treated patients (4.15). In memantine users, mortality rates were similar for placebo-treated (4.49) and galantamine-treated patients (5.57). In memantine nonusers at 24 months, the decline in MMSE scores (effect size (95 % CI) 0.25 (0.14; 0.36)) and DAD scores (0.17 (0.06; 0.28)) from baseline was lower

Full Text available with Trip Pro

2016 Alzheimer's research & therapy

30. Functional connectivity increase in the default-mode network of patients with Alzheimer׳s disease after long-term treatment with Galantamine. (PubMed)

Functional connectivity increase in the default-mode network of patients with Alzheimer׳s disease after long-term treatment with Galantamine. Acetylcholinesterase inhibitors (AChEIs) are efficacious for the treatment of mild to moderate forms of Alzheimer's dementia (AD). Default-mode network (DMN) connectivity is considered to be early impaired in AD. Long-term effects of AChEIs on the DMN in AD have not yet been investigated. Twenty-eight AD patients and 11 age-matched healthy volunteers (HC (...) ) participated in the prospective study. AD patients were randomly assigned to either a pharmacotherapy arm (Galantamine, AD G) or to a placebo arm (AD P+G) for the period of 6 months followed by open-label Galantamine therapy from month 7-12. All subjects underwent neuropsychological testing, resting-state functional and structural MRI at baseline and after 12 months, AD patients additionally in between after 6 months. Thirteen AD patients completed the treatment trial and underwent all functional MRI

2016 European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

31. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine (PubMed)

Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) project designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia, identified three drug mechanisms of particular interest: dopaminergic, cholinergic, and glutamatergic. Galantamine is an acetylcholinesterase inhibitor and a positive (...) allosteric modulator of the α7 nicotinic receptors. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist. There is evidence to suggest that the combination of galantamine and memantine may be effective in the treatment of cognitive impairments in schizophrenia. There is a growing body of evidence that excess kynurenic acid (KYNA) is associated with cognitive impairments in schizophrenia. The α-7 nicotinic and the NMDA receptors may counteract the effects of kynurenic acid (KYNA) resulting

Full Text available with Trip Pro

2016 Schizophrenia Research: Cognition

32. Galantamine

Galantamine Galantamine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Galantamine Galantamine Aka: Galantamine , Reminyl , Razadyne (...) : 16 mg orally daily for at least 4 weeks Consider increase to 24 mg orally daily if indicated VI. Adverse Effects See has also been reported with Galantamine VII. Efficacy Moderately preserved cognitive function for >6 months References VIII. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Galantamine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip

2018 FP Notebook

33. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Alzheimer’s disease (AD) is the most commonly occurring form of dementia. It is predominantly a disease of later life, affecting 5% of those over 65 in the UK.Review and update guidance to the NHS in England and Wales on the clinical effectiveness and cost-effectiveness (...) of donepezil, galantamine, rivastigmine [acetylcholinesterase inhibitors (AChEIs)] and memantine within their licensed indications for the treatment of AD, which was issued in November 2006 (amended September 2007 and August 2009).Electronic databases were searched for systematic reviews and/or metaanalyses, randomised controlled trials (RCTs) and ongoing research in November 2009 and updated in March 2010; this updated search revealed no new includable studies. The databases searched included The Cochrane

2016 Health technology assessment (Winchester, England)

34. Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). (PubMed)

Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). The effects of galantamine (GAL) on quality of life (QoL) and cognitive speed, as well its effects combined with nimodipine (NIM) in Alzheimer disease (AD) with cerebrovascular disease (mixed dementia), have not been explored.Double-blind, placebo-controlled, multicenter Brazilian trial, studying

2014 Arquivos de neuro-psiquiatria

35. Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia

Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia Oremus M, Santaguida P, Raina P CRD summary The review concluded that galantamine was superior to placebo in patients with dementia after a maximum six-month follow-up. There was no evidence of a benefit compared (...) with donepezil. The authors stated that the evidence needed careful interpretation and further research was needed. Data limitations and potential review biases mean that the authors' recommendation to interpret the evidence carefully is appropriate. Authors' objectives To determine the efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia. Searching EMBASE, CINAHL, AgeLine, PsycINFO, MEDLINE, PREMEDLINE, AMED and Cochrane Central Register of Controlled Trials (CENTRAL

Full Text available with Trip Pro

2010 DARE.

36. Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial (PubMed)

Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial Metabolic syndrome (MetS) is an obesity-driven condition of pandemic proportions that increases the risk of type 2 diabetes and cardiovascular disease. Pathophysiological mechanisms are poorly understood, though inflammation has been implicated in MetS pathogenesis. The aim of this study was to assess the effects of galantamine, a centrally acting acetylcholinesterase inhibitor (...) with antiinflammatory properties, on markers of inflammation implicated in insulin resistance and cardiovascular risk, and other metabolic and cardiovascular indices in subjects with MetS.In this randomized, double-blind, placebo-controlled trial, subjects with MetS (30 per group) received oral galantamine 8 mg daily for 4 weeks, followed by 16 mg daily for 8 weeks or placebo. The primary outcome was inflammation assessed through plasma levels of cytokines and adipokines associated with MetS. Secondary endpoints

Full Text available with Trip Pro

2017 JCI insight

37. Galantamine for dementia in people with Down syndrome. (PubMed)

Galantamine for dementia in people with Down syndrome. Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome (DS). Acetylcholine is a chemical found in the brain that has an important role in memory, attention, reason and language. Galantamine both inhibits the activity of acetylcholinesterase and increases the level of acetylcholine. Galantamine can improve cognitive function and slow the decline of AD in the general population over time. It is important (...) to note that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population.To determine the effectiveness and safety of galantamine for people with DS who develop AD.CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, BIOSIS, SCI, SSCI and the NRR were searched up to October 2008. We contacted the manufacturers of galantamine

2009 Cochrane

38. First in human study with a prodrug of galantamine: Improved benefit-risk ratio? (PubMed)

First in human study with a prodrug of galantamine: Improved benefit-risk ratio? Gln-1062 (Memogain) is a pharmacologically inactive prodrug of galantamine. Owing to its lipophilic nature, it preferentially enters the brain, where it is cleaved into active galantamine. Gln-1062 is expected to have fewer peripheral side effects than other cholinesterase inhibitors, with improved effectiveness.This was a double-blind, comparator and placebo-controlled, sequential cohort, single ascending dose (...) study in 58 healthy subjects with Gln-1062 in doses of 5.5, 11, 22, 33, and 44 mg, compared with oral galantamine 16 mg and donepezil 10 mg. Safety, tolerability, pharmacokinetics, and pharmacodynamics were assessed.Gln-1062 doses up to 33 mg were well tolerated and induced a dose-dependent increase in the plasma concentrations of Gln-1062 and galantamine. Gln-1062 had a dose-dependent positive effect on verbal memory and attention, mainly in the first hours after drug administration.Gln-1062

Full Text available with Trip Pro

2016 Alzheimer's & dementia : translational research & clinical interventions

39. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#39

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Overview | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 20 June 2018 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (NG97) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects recommendations 1.1, 1.2, 1.4, 1.5 and 1.6. Recommendation 1.3 was updated in June 2018 in NICE’s guideline on dementia (NG97

2011 National Institute for Health and Clinical Excellence - Technology Appraisals

40. Donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease: a Bayesian network meta-analysis

Donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease: a Bayesian network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>